CYGNOS BioTech
Biotechnology Research • 
P.O. Box 160471, Miami, United States • 1-10 Employees
Company overview
| Headquarters | P.O. Box 160471, Miami, FL 33116-0471, US |
| Website | |
| NAICS | 541714 |
| Founded | 2022 |
| Employees | 1-10 |
Key Contact at CYGNOS BioTech
Walid Chaar
Chief Technology Officer
CYGNOS BioTech Email Formats
CYGNOS BioTech uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@cygnosbiotech.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@cygnosbiotech.com | 100% |
About CYGNOS BioTech
CYGNOS BioTech is developing propriety antimicrobial therapeutics protected under several patents. PVX that will be commercialized for human and veterinary clinical markets. PVX is currently manufactured by chemical modification of the protein to ultimately promote biologic activity, either antiviral or antitumor (MMX). CYGNOS PVX has already demonstrated efficacy in companion animals (dogs, cats, horses and birds). CYGNOS has been awarded 2 FDA investigational product INADs for PVX and MMX. In parallel, CYGNOS is seeking funding to advance product development through FDA for the approval of the Animal INADs and a Human IND submission.
CYGNOS BioTech revenue & valuation
| Annual revenue | $256,665 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $821,328 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
CYGNOS BioTech has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
CYGNOS BioTech has never raised funding before.
United Kingdom
Frequently asked questions
4.8
40,000 users
